Ultragenyx Pharmaceutical Deal History & Licensing Activity
Ultragenyx Pharmaceutical is a biotech headquartered in US. Over the past three years, Ultragenyx Pharmaceutical has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (2 deals).
Deals (12mo)
1
Active Trials
12
Top Modality
Other
Focus Area
Rare Disease
Ultragenyx Pharmaceutical Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Ultragenyx Pharmaceutical in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Dimension Therapeutics portfolio | Ultragenyx | Other | Preclinical | acquisition | Apr 2026 |
Ultragenyx Pharmaceutical Pipeline Focus
Therapeutic areas and modalities where Ultragenyx Pharmaceutical is most active based on deal history and clinical trial data.
Therapeutic Areas
Ultragenyx Pharmaceutical Strategic Signals
Key indicators of Ultragenyx Pharmaceutical's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Ultragenyx Pharmaceutical's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Mab Benchmarks
Upfront, milestone, and royalty benchmarks for mab deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Ultragenyx Pharmaceutical Licensing & Deal Activity
Ultragenyx Pharmaceutical is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Ultragenyx Pharmaceutical ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Ultragenyx Pharmaceutical include Rare Disease (3 deals and trials). In terms of modality, Ultragenyx Pharmaceutical has shown particular interest in other, mab.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Ultragenyx Pharmaceutical and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Ultragenyx Pharmaceutical's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.